Improved Accuracy and Reliability of PRIMARY Scoring Using Delayed [68Ga] Ga-PSMA PET/CT Imaging.
Kaan Akçay, Gamze Beydağı, Onur Erdem Şahin...
https://pubmed.ncbi.nlm.nih.gov/39917984/Actively Recruiting
Led by Istanbul University - Cerrahpasa · Updated on 2025-09-15
201
Participants Needed
10
Research Sites
89 weeks
Total Duration
Researchers are investigating the Istanbul PSMA PETCT Criteria IPPC to improve the selection of men with biopsy-confirmed low-risk prostate cancer ISUP Grade 1 for active surveillance. This multicenter, prospective diagnostic accuracy study aims to refine patient classification by integrating delayed Ga-68 PSMA PETCT imaging, potentially reducing unnecessary biopsies and MRI scans while avoiding under-treatment of higher-risk patients. The study compares IPPC with standard mpMRI and biopsy results, using radical prostatectomy pathology or long-term clinical follow-up as benchmarks. Participants undergo delayed 120-minute Ga-68 PSMA PETCT scans assessed by the IPPC, which categorizes prostate lesions into three risk levels low uptake safe for monitoring, indeterminate uptake active surveillance with close follow-up, and high uptake recommendation for treatment. This procedure is added to the existing diagnostic pathway involving mpMRI and prostate biopsy performed within three months before enrollment. During the study, participants diagnostic results will be monitored against clinical outcomes, including pathology from prostatectomy or follow-up over two years. Researchers will measure the diagnostic accuracy of IPPC for detecting clinically significant prostate cancer and assess its impact on reducing repeat biopsy rates. Participants must have no prior PSMA PET imaging and will be followed according to the studys schedule, with safety and effectiveness monitored through imaging and clinical data over the study period.
CONDITIONS
Study of PSMA PET/CT Imaging to Help Select Men With Low-Risk Prostate Cancer for Active Surveillance
L
Levent Kabasakal, Prof. MD
N
Nalan Alan, Prof. MD.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Istanbul University - Cerrahpasa
Lead Sponsor
Yeditepe University
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit
Duration - Within 1 month
Participants undergo delayed Ga-68 PSMA PET/CT scans evaluated using the Istanbul PSMA PET/CT Criteria. Results are compared with prior biopsy and mpMRI findings to classify cancer risk.
1 visit
Duration - Up to 2 years
Participants are monitored through clinical follow-up for up to 2 years to evaluate cancer progression and the need for further biopsies or treatment.
Regular clinical assessments as scheduled
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Have more questions? Get in touch with our team for quick support
Kaan Akçay, Gamze Beydağı, Onur Erdem Şahin...
https://pubmed.ncbi.nlm.nih.gov/39917984/Kaan Akcay, Ali Kibar, Onur Erdem Sahin...
https://pubmed.ncbi.nlm.nih.gov/38112777/Philip Cornford, Roderick C N van den Bergh, Erik Briers...
https://pubmed.ncbi.nlm.nih.gov/38614820/Louise Emmett, Nathan Papa, James Buteau...
https://pubmed.ncbi.nlm.nih.gov/35301240/Istanbul University - Cerrahpasa
Lead Sponsor
Yeditepe University
Collaborating Sponsor